In contrast, regions where control patient samples are segregated tend to have low intensities of most of the immune markers observed, whereas AKI-other regions show intermediate intensities for many of the markers, with some evidence of increased signal in CD11b, FoxP3, CD14, and CD16, also matching some of the differences observed in marker abundance in Supplementary Table S15. This evidence concerns the gene FOXP3 and acute kidney injury.